Evaluating a fertility-preserving treatment for early-stage endometrial cancer and hyperplasia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the effectiveness and side effects of a membrane-inhibiting formula combined with oral progestins as a treatment option for women of childbearing age diagnosed with early-stage endometrial cancer and hyperplasia. Participants will take the treatment daily and attend clinic visits every three months for checkups, tests, and hysteroscopy. The study will investigate the time to complete endometrial remission, potential medical issues arising from the treatment, and outcomes related to pregnancy and recurrence across different molecular classifications of the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1.18-45 years old with a strong desire to preserve fertility; 2. pathologically diagnosed with primary grade1 or grade2 endometrioid endometrial carcinoma and hyperplasia 3.no signs of suspicious myometrial invasion by enhanced magnetic resonance imaging (MRI) 4. no signs of suspicious extrauterine metastasis by enhanced computed tomography and CT scan of the Lungs

Exclusion Criteria:

* 1.have contraindication for pregnancy. 2.no fertility requiremen 3.have myometrial invasion or extrauterine metastasis 4.pathologically diagnosed with primary grade3 endometrioid endometrial carcinoma or non-endometrioid endometrial carcinoma 5.Any disease or symptom that may affect the implementation of the study or the interpretation of the results

Where it's running

• Women's Hospital School of Medicine Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Yang Li, Doctor — Women's Hospital School Of Medicine Zhejiang University
• Study coordinator: Yang Li, Doctor
• Email: 5516015@zju.edu.cn
• Phone: 0086-18268165386

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Progestins before surgery for endometrial cancer or precancers

  This phase II study tests two progestin options (megestrol acetate vs. micronized progesterone) for women with endometrial cancer or atypical endometrial hyperplasia before they have surgery.

  Recruiting at 2 sites Phase 2 New Mexico Cancer Research Alliance · Iowa City, Iowa and 3 other locations · NCT07436793

• Fertility-preserving hysteroscopic treatment outcomes for endometrial cancer and atypical hyperplasia

  This project tests whether removing lesions by hysteroscopy combined with hormonal therapy helps women with endometrial cancer or atypical hyperplasia preserve fertility and achieve good pregnancy and cancer-control outcomes.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07077876

• Tracking outcomes of uterine cavity conditions after hysteroscopy

  This project will follow adults with endometrial polyps, hyperplasia, or cancer who undergo hysteroscopy to see if detailed clinical and pathology data can predict disease course over one year.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07048327

• Two-point versus four-point cervical methylene blue injections for sentinel lymph node mapping in stage I endometrial cancer

  This test checks whether using four cervical methylene blue injections instead of the usual two helps surgeons find sentinel lymph nodes in people with newly diagnosed stage I endometrial cancer who are having surgery.

  Recruiting at 2 sites Dokuz Eylul University · Ankara and 1 other locations · NCT07040657

• Using ultrasound to guide endometrial biopsies for post-menopausal bleeding

  This study is testing if using ultrasound to guide endometrial biopsies can help women with post-menopausal bleeding get better tissue samples and avoid more invasive procedures.

  Recruiting Imperial College Healthcare NHS Trust · London · NCT06501846

• Evaluating dostarlimab as a non-surgical treatment for early-stage endometrial cancer

  This study is testing if a new immunotherapy drug called dostarlimab can be a safe and effective non-surgical treatment for women with early-stage endometrial cancer who want to keep their fertility or can't have surgery.

  Recruiting at 2 sites Phase 2 Queensland Centre for Gynaecological Cancer · Sydney, New South Wales and 2 other locations · NCT06278857

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.